In a 6-month, four-arm randomized phase II trial of 110 high-risk women (mean age 52, BMI 25), low-dose tamoxifen (10 mg every other day) significantly raised sex hormone-binding globulin and IGFBP-3 while lowering IGF-I. Intermittent caloric restriction (ICR) arms showed higher adiponectin than non-ICR arms. Among women adherent above 90%, lifestyle plus ICR raised SHBG more than lifestyle alone (p=0.045). Adverse events did not differ between arms, though tamoxifen modestly worsened quality of life.

These are biomarker changes, not cancer outcomes, and the authors rightly note SHBG is not a validated surrogate for breast cancer risk. The tamoxifen result is the expected one: it echoes earlier low-dose work, including the TAM-01 trial, where 5 mg daily cut recurrence in intraepithelial neoplasia, so the signal here is confirmatory. The more interesting question is whether fasting adds anything beyond weight loss. Participants were close to normal weight, which makes the adiponectin rise intriguing, since most ICR benefits in the literature appear in overweight women. The one SHBG finding for ICR came from a post hoc adherent subgroup with a borderline p-value, so treat it as hypothesis-generating. With 110 participants split four ways, six months of follow-up, and no mammographic density or incidence data, the trial cannot say whether combining the strategies lowers cancer risk. Women at high risk should discuss low-dose tamoxifen with their oncologist; the fasting component remains experimental. Incremental, but a useful template for larger, longer trials.